CAGE Inhibitors
The class of CAGE inhibitors encompasses a diverse array of chemicals that exert their influence on CAGE either directly or indirectly, revealing intricate regulatory networks governing this protein. Sorafenib, a multikinase inhibitor, indirectly modulates CAGE by targeting the RAF/MEK/ERK pathway. This highlights the potential role of MAPK signaling in regulating CAGE activity, offering insights into the interconnectedness of signaling pathways within the cellular milieu. Dasatinib, a tyrosine kinase inhibitor, indirectly influences CAGE by targeting SRC family kinases, disrupting downstream signaling pathways. This unveils the interconnected nature of tyrosine kinase signaling networks and their potential roles in modulating CAGE function. JQ1, a BET protein inhibitor, indirectly modulates CAGE by disrupting chromatin-mediated regulation, providing insights into the epigenetic regulation of CAGE expression and function. Ruxolitinib, a JAK1/2 inhibitor, indirectly influences CAGE by targeting the JAK/STAT pathway, revealing potential connections between JAK/STAT signaling and CAGE function.
LDN-193189, a BMP receptor inhibitor, indirectly modulates CAGE by targeting BMP signaling, highlighting the potential crosstalk between BMP signaling and CAGE function. LGK-974, a Wnt pathway inhibitor, indirectly influences CAGE by targeting Wnt signaling, revealing regulatory connections within the context of intracellular signaling networks. NVP-BEZ235, a dual PI3K/mTOR inhibitor, indirectly modulates CAGE by targeting the PI3K/AKT/mTOR pathway, offering insights into the potential involvement of PI3K/AKT/mTOR signaling in governing CAGE function. AG-490, a JAK2 inhibitor, indirectly influences CAGE by targeting the JAK/STAT pathway, uncovering potential regulatory roles of JAK/STAT signaling in modulating CAGE function. This diverse class of CAGE inhibitors provides valuable tools for investigating the regulatory mechanisms governing CAGE and its interconnectedness with various signaling pathways. The indirect modulation by these chemicals offers a nuanced understanding of how CAGE function is intricately regulated within the complex landscape of cellular signaling networks.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multikinase inhibitor that indirectly influences CAGE by targeting the RAF/MEK/ERK pathway. By inhibiting RAF kinases, Sorafenib disrupts downstream signaling, impacting cellular processes related to CAGE. This indirect modulation provides insights into the potential regulatory mechanisms governing CAGE activity within the context of MAPK signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that indirectly modulates CAGE by targeting SRC family kinases. The inhibition of these kinases disrupts downstream signaling pathways, influencing cellular processes related to CAGE. Dasatinib's impact on CAGE offers a unique perspective into the interconnectedness of tyrosine kinase signaling networks and their potential roles in regulating CAGE function. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 is a bromodomain and extraterminal (BET) protein inhibitor that indirectly influences CAGE by disrupting chromatin-mediated regulation. By inhibiting BET proteins, JQ1 modulates gene expression patterns, potentially impacting cellular processes related to CAGE. This epigenetic modulation sheds light on the intricate regulatory networks that may govern CAGE expression and function within the context of chromatin dynamics. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB-431542 is a selective inhibitor of the TGF-β receptor that indirectly modulates CAGE by targeting TGF-β signaling. The inhibition of TGF-β receptor blocks downstream signaling, influencing cellular processes related to CAGE. This indirect regulation highlights the potential crosstalk between TGF-β signaling and CAGE function, providing insights into the regulatory mechanisms governing CAGE within the context of TGF-β-mediated cellular responses. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective inhibitor of MEK1/2 that indirectly influences CAGE by targeting the MAPK/ERK pathway. By inhibiting MEK1/2, PD 98059 disrupts downstream signaling, impacting cellular processes related to CAGE. This indirect modulation provides insights into the potential roles of MAPK/ERK signaling in regulating CAGE function within the context of intracellular signaling cascades. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $184.00 $195.00 | 2 | |
GDC-0941 is a selective inhibitor of PI3K that indirectly influences CAGE by targeting the PI3K/AKT/mTOR pathway. The inhibition of PI3K disrupts downstream signaling, influencing cellular processes related to CAGE. This indirect modulation sheds light on the potential involvement of PI3K/AKT/mTOR signaling in regulating CAGE function within the context of intracellular signaling networks. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
A769662 is an AMP-activated protein kinase (AMPK) activator that indirectly modulates CAGE by influencing cellular energy status. By activating AMPK, A769662 may impact cellular processes related to CAGE, revealing potential connections between energy sensing and CAGE function. This indirect modulation provides insights into the potential regulatory roles of cellular energy status in governing CAGE activity. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a JAK1/2 inhibitor that indirectly influences CAGE by targeting the JAK/STAT pathway. The inhibition of JAK1/2 disrupts downstream signaling, impacting cellular processes related to CAGE. This indirect modulation provides insights into the potential involvement of JAK/STAT signaling in regulating CAGE function within the context of intracellular signaling networks. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 is a selective BMP receptor inhibitor that indirectly modulates CAGE by targeting BMP signaling. The inhibition of BMP receptors disrupts downstream signaling, influencing cellular processes related to CAGE. This indirect regulation sheds light on the potential crosstalk between BMP signaling and CAGE function, providing insights into the regulatory mechanisms governing CAGE within the context of BMP-mediated cellular responses. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $352.00 $1270.00 | 2 | |
LGK-974 is a Wnt pathway inhibitor that indirectly influences CAGE by targeting Wnt signaling. The inhibition of Wnt signaling disrupts downstream pathways, impacting cellular processes related to CAGE. This indirect modulation provides insights into the potential crosstalk between Wnt signaling and CAGE function, revealing regulatory connections within the context of intracellular signaling networks. | ||||||